Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patienttransplantleukemialimitcell
  Phrases that lowered it: lenalidomideallergicsurface antigenhivelderly
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 60 (lowers risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Drug's FAERS reports with a death: 34.7% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 25 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 95.6% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 24 (lowers risk) · Sponsor's track record
• Maximum age: 80 (lowers risk) · Who can join
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 10215 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) NCT00890929 · started 2009 · scored riskier than 99% of active trials completed
• Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS NCT01442714 · started 2011 · scored riskier than 70% of active trials terminated
• Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome NCT01433965 · started 2012 · scored riskier than 99% of active trials completed
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant NCT01419795 · started 2012 · scored riskier than 81% of active trials terminated
• Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML NCT02255162 · started 2015 · scored riskier than 95% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.